Clinical validation should determine whether pre-intervention NRG1 thresholds can identify patients most likely to benefit from moderate-intensity endurance protocols, particularly those with ischemic cardiomyopathy, where NRG1/ErbB signaling is essential for angiogenesis and fibrosis regression. This evidence concerns the gene NRG1 and ischemic cardiomyopathy.